Clinical trial
Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: a 24 Weeks Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Group, International, Multi-center Phase III Study Evaluating Efficacy and Safety of Rotigotine 4 Mg/24 Hrs in Combination with Rivastigmine 9.5 Mg/24 Hrs in Mild to Moderate Alzheimer's Disease Patients.
NCT06702124 is registered in ClinicalTrials.gov with I.R.C.C.S. Fondazione Santa Lucia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: a 24 Weeks Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Group, International, Multi-center Phase III Study Evaluating Efficacy and Safety of Rotigotine 4 Mg/24 Hrs in Combination with Rivastigmine 9.5 Mg/24 Hrs in Mild to Moderate Alzheimer's Disease Patients.
- Lead sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2023
- Completion date
- April 30, 2026
- Enrollment
- 348 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.